logo
Plus   Neg
Share
Email

Precision Castparts Closes Acquisition Of Titanium Metals

Precision Castparts Corp. (PCP) announced that it has completed its acquisition of Titanium Metals Corp. (TIE) or Timet.

Timet has been a subsidiary of ELIT Acquisition Sub Corp., a wholly-owned subsidiary of Precision Castparts, since December 21, 2012. Acquisition Sub, as the owner of more than 90% of the outstanding shares of Timet common stock, completed a short-form merger with Timet on January 7, 2013, as a result of which Timet became a wholly-owned subsidiary of Precision Castparts. Each remaining share of Timet common stock not tendered in Precision Castparts' previous tender offer for Timet shares was converted in the merger into the right to receive $16.50 without interest and less any applicable withholding of taxes.

As a result of the merger, Timet common stock will cease to be traded on the New York Stock Exchange.

On November 9, 2012, Precision Castparts and Timet had signed a definitive merger agreement, by which the tender offer would be made.

On November 20, 2012, Precision Castparts announced that its wholly owned subsidiary, ELIT Acquisition Sub Corp. has commenced the tender offer for all of the outstanding shares of common stock of Titanium Metals at a price of $16.50 per share, net to the seller in cash, without interest and less any required withholding of tax.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT